Sophie Vieujean
YOU?
Author Swipe
View article: Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora Study
Acute Pancreatitis in Inflammatory Bowel Disease: Results from the European Pandora Study Open
Background and aims: An increased risk of acute pancreatitis (AP) has been reported in patients with inflammatory bowel disease (IBD), but data on its prevalence, etiology, and outcomes are limited. Materials and Methods: A two-step retros…
View article: The CROCO (CROhn’s Disease COhort Study) – study design and protocol
The CROCO (CROhn’s Disease COhort Study) – study design and protocol Open
Background: Crohn’s disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The Lémann Index (LI) is a validated tool for measuring cumulative bowel…
View article: Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis Open
Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.
View article: Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review Open
Background and Aims The Food and Drug Administration (FDA) and European Medicines Agency (EMA) ensure the safety, efficacy, and security of treatments, including therapies for immune-mediated disorders such as inflammatory bowel disease (I…
View article: Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study
Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study Open
This is the first study characterizing this adverse event in JAK inhibitor-treated patients with IBD and presents the largest cohort of JAK inhibitor-induced acne cases across all immune-mediated diseases. Acne is a common adverse effect r…
View article: Effectiveness and Safety of a Second <scp>JAK</scp> Inhibitor in Ulcerative Colitis: The <scp>J2J</scp> Multicentre Study
Effectiveness and Safety of a Second <span>JAK</span> Inhibitor in Ulcerative Colitis: The <span>J2J</span> Multicentre Study Open
Background While three Janus kinase inhibitors (JAKi) have demonstrated efficacy in ulcerative colitis (UC), scarce data exist regarding JAKi intraclass switching. Aim To evaluate the effectiveness and safety of a second JAK inhibitor in U…
View article: Fidaxomicin for <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study
Fidaxomicin for <i>Clostridioides difficile</i> infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study Open
Background and aims Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remain scarce. We assessed the effectiveness and safety o…
View article: Confocal Endomicroscopy Intestinal Epithelial Barrier Abnormalities in Individuals Without Documented Gastro‐Intestinal Disease
Confocal Endomicroscopy Intestinal Epithelial Barrier Abnormalities in Individuals Without Documented Gastro‐Intestinal Disease Open
Background and aims Probe‐based confocal endomicroscopy (pCLE) allows real‐time microscopic visualization of the intestinal mucosa surface layers. Despite remission achieved through anti‐tumor necrosis factor or vedolizumab therapy, anomal…
View article: P0129 Distinct involvement of plasma cells and monocytes/macrophages in ileal and colonic ulcer formation in patients with Crohn's disease
P0129 Distinct involvement of plasma cells and monocytes/macrophages in ileal and colonic ulcer formation in patients with Crohn's disease Open
Background Despite its interest for the development of personalised medicine, the pathophysiological distinctions between ileal and colonic Crohn’s disease (CD) have been poorly characterised. This study aims to search for immunological di…
View article: Integrated cell type-specific analysis of blood and gut identifies matching eQTL for 140 IBD risk loci and entrectinib as possible repurposing candidate
Integrated cell type-specific analysis of blood and gut identifies matching eQTL for 140 IBD risk loci and entrectinib as possible repurposing candidate Open
Genes whose expression is affected in a consistent manner by GWAS-identified risk variants and the disease process, constitute preferred drug targets. We herein combine integrated cis-eQTL analysis in 27 blood cell populations and 43 intes…
View article: External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab Open
Objective In patients with Crohn’s disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn’s disease patients in stable Remission on combi…
View article: Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease
Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease Open
View article: Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study Open
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the risk of postoperative complications of tofacitinib exposure before colectomy in comparison w…
View article: DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease
DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease Open
Background Crohn’s disease (CD) progression can lead to bowel damage (BD) and disability. However, the longitudinal characterization of BD and disability in early CD patients remains limited. Methods The Crohn´s Disease Cohort (CROCO) is a…
View article: P735 JAK inhibitors and S1P receptor modulators for the treatment of antibiotic refractory chronic pouchitis: an ECCO CONFER Multicentre Case Series
P735 JAK inhibitors and S1P receptor modulators for the treatment of antibiotic refractory chronic pouchitis: an ECCO CONFER Multicentre Case Series Open
Background Data regarding effectiveness and safety of JAK inhibitors and S1P receptor modulators in chronic antibiotic refractory pouchitis (CARP) are lacking. This ECCO-CONFER project collected cases of CARP treated with JAK inhibitors or…
View article: P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study
P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study Open
Background Both the American Gastroenterological Association (AGA) and the European Crohn's and Colitis Organisation (ECCO) recommend to continue biologic during the whole pregnancy and until the third trimester, respectively. However, the…
View article: DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort Open
Background Microscopic colitis (MC) is a chronic inflammatory condition of the colon, resulting in an impaired quality of life due to debilitating watery diarrhea. First-line therapy consists of budesonide, though a subset of patients is r…
View article: P508 Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study
P508 Pre-operative exposure to tofacitinib is as safe as biologics in patients with ulcerative colitis undergoing colectomy: a multicentre observational study Open
Background Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is …
View article: P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study
P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study Open
Background Crohn’s disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability…
View article: P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series
P621 Safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series Open
Background Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease often necessitating liver transplantation (LTX). Approximately 70% of PSC patients have a concomitant diagnosis of inflammatory bowel diseas…
View article: P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE
P766 No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPARE Open
Background In the SPARE trial, the discontinuation of infliximab (IFX) in patients with Crohn’s disease (CD) in sustained remission under combination therapy (IFX and immunosuppressant therapy), was associated with a significantly higher r…
View article: P397 Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease
P397 Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease Open
Background Ileal and colonic Crohn’s disease (CD) are nowadays considered as separate entities. Studies are needed to better characterise the biological specificities of these subphenotypes. In fine, this research should offer opportunitie…
View article: Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study Open
View article: Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn’s disease
Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn’s disease Open
The significant increase of plasmatic dp-ucMGP levels with age, disease duration and the trend observed in patients with non-ulcerated strictures may suggest that this extracellular matrix protein could be a marker of tissue remodelling an…
View article: Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey
Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey Open
The gut microbiota play a pivotal role in human health. Dysbiosis, alterations in microbiota composition and function, is associated with gastrointestinal disorders, including inflammatory bowel disease (IBD). This international survey aim…
View article: Treatment of Antibiotic Refractory Chronic Pouchitis With JAK Inhibitors and S1P Receptor Modulators: An ECCO CONFER Multicentre Case Series
Treatment of Antibiotic Refractory Chronic Pouchitis With JAK Inhibitors and S1P Receptor Modulators: An ECCO CONFER Multicentre Case Series Open
Background and Aims Data regarding the effectiveness and safety of Janus kinase [JAK] inhibitors and sphingosine-1-phosphate [S1P] receptor modulators in antibiotic refractory chronic pouchitis [CARP] are lacking. Methods This ECCO-CONFER …
View article: Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA
Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA Open
Background Inflammatory bowel disease [IBD] is associated with an increased risk of developing lymphoma. Although recent data have clarified the epidemiology of lymphoma in IBD patients, the clinical and pathological characteristics of lym…
View article: Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions
Defining Biological Remission in Crohn’s Disease: Interest, Challenges and Future Directions Open
In Crohn’s disease, the treat-to-target strategy has been greatly encouraged and has become a standard of care. In this context, defining the target [remission] constitutes a major stake and is fuelling the literature. Currently, clinical …
View article: Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey Open
Background: Treatment choices for patients with inflammatory bowel disease (IBD) are based on the balance between risks and benefits. Our AI was to compare the perspectives of patients and physicians in evaluating the risks and benefits be…
View article: Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic Open
Background Patients with inflammatory bowel disease (IBD) consider that their diet is important for controlling symptoms and frequently ask their physician for additional guidance on this matter. The objectives of the present study of pati…